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Summary 
Chemotactic cytokines of the CC subfamily (CC chemokines) are considered as major media- 
tors of allergic inflammation owing to their actions on basophil and eosinophil leukocytes. The 
monocyte chemotactic protein (MCP)  1 is a potent inducer of mediator release from basophils 
but is inactive on eosinophils. To obtain information on the structural determinants of the ac- 
tivities of MCP-1, we have synthesized several NH2-terminally truncated analogues and tested 
their  effects on  basophils  and  eosinophils.  Through  deletion  of the  NH2-terminal  residue, 
MCP-1(2-76) was obtained, which was a potent activator of eosinophils, as assessed by chemo- 
taxis,  cytosolic free Ca  2+  changes,  actin polymerization, and the induction  of the respiratory 
burst.  In contrast,  the  activity of MCP-I(2-76)  on basophil leukocytes was dramatically de- 
creased (50-fold) compared with that of full-length MCP-1. Deletion of the next residue led to 
total loss of activity on eosinophil and basophil leukocytes. Analogues with three or four resi- 
due deletions,  MCP-1(4-76)  and MCP-1(5-76),  were again active on both cells,  whereas all 
further truncation  analogues,  MCP-l(6-76)  through  MCP-1(10-76),  were inactive.  Thus,  a 
minimal structural modification can change receptor and target cell selectivity of MCP-1. Our 
observations indicate that the recognition sites of CC chemokine receptors on eosinophils and 
basophils are similar, although they discriminate between MCP-1  and MCP-l(2-76)  and sug- 
gest NH2-terrninal processing as a potential mechanism for the regulation of CC chemokine 
activities. 
E 
osinophil  and  basophil  leukocytes  are  major  effector 
cells  in  allergic  inflammation.  Recent  studies  have 
demonstrated that some chemotactic cytokines of the  CC 
subfamily (CC  chemokines),  in  addition  to  their  activity 
toward monocytes (1-4)  and T  cell subsets  (5-8),  can at- 
tract and activate eosinophils and basophils (9-15). Mono- 
cyte chemoattractant protein (MCP)  1, the best-character- 
ized CC chemokine, is a moderate chemoattractant and a 
powerful stimulus of histamine and leukotriene release for 
basophils but does not act on eosinophils  (9-11).  In con- 
trast,  regulated on activation, normal T  expressed and se- 
creted  (R.ANTES)  and macrophage inflammatory protein 
(MIP)-la are strong attractants for both types of cells but 
only weak inducers  of release  (12-14).  MCP-3  combines 
the properties of MCP-1  and RANTES and is a powerful 
stimulus  of both  release  and  migration  for basophils  and 
eosinophils  (15).  The  differences in  the  responsiveness of 
these  cells  are  likely  to  depend  on  the  patterns  of CC 
chemokine receptor expression (15). 
It is well established that the NH2-terminal region is crit- 
ical for the biological activity of IL-8 (16,  17),  and it has 
been shown that modifications of the corresponding region 
of MCP-1  profoundly alter the activity of this CC chemo- 
kine on mononuclear phagocytes (18,  19).  We have now 
studied the role of the NH2-terminal domain for the activ- 
ity of MCP-1  on eosinophils and basophils and show here 
that  deletion  of  the  NH2-terminal  residue  confers  to 
MCP-1  potent  activity  on  eosinophil  leukocytes  while 
greatly reducing activity on basophils. 
Materials and Methods 
Cytokines and Other Agonists.  All chemokines and chemokine 
analogues  were prepared on peptide  synthesizer  (model  430A; 
Applied Biosystems, Inc., Foster City, CA), using the tertiary bu- 
tyloxycarbonyl  and benzyl protection strategy (19), and C5a was 
purified from human plasma (20). Recombinant human IL-3 was 
kindly provided by Sandoz Ltd. (Basel, Switzerland). All MCP-1 
truncation  analogs were analyzed by reverse-phase  HPLC, and 
each  was  eluted  as  a  single,  uniform peak without  detectable 
closely eluting species. Each analogue was also subjected to elec- 
trospray  mass spectrometry,  and  the  determined  mass corre- 
sponded in all cases to the calculated mass within the experimen- 
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in parentheses,  the difference from the calculated average mass is 
as follows: MCP-1(2-76), 8,552.2  +-  1.1  (-0.8); MCP-l(3-76), 
8,455.1  +-  0.9  (-0.7);  MCP-l(4-76),  8,340.6  +  1.5  (-0.1); 
MCP-1(5-76), 8,269.8  +  0.6 (+0.I); MCP-l(6-76), 8,I56.0 + 
0.8 (+0.5); MCP-l(7-76), 8,041.8 -  0.7 (-0.6); MCP-l(8-76), 
7,971.2  _  0.8  (-0.1);  MCP-l(10-76), 7,774.9  +  0.6  (-0.2). 
MCP-1,  MCP-3,  and R_ANTES were  characterized  in former 
studies (4). 
Cells.  Leukocytes  were isolated from freshly drawn blood of 
healthy,  unselected donors by dextran sedimentation for 90 min. 
Basophils were partially purified (10-30% pure, with lymphocytes 
as almost exclusive contaminants) on a discontinuous Percoll gra- 
dient (21). Eosinophils  (99% pure) were obtained by Percoll den- 
sity gradient centrifugation followed by negative selection  with 
anti-CD  16 mAb--coated magnetic beads (12). 
Histamine and Leukotriene C4(LTC4) Release.  A  suspension  of 
basophils  (200,000  cells/ml)  in I-IACM buffer (20  mM Hepes, 
pH 7.4, containing 125 mM NaC1, 5 mM KC1, 1 mM MgC12, 1 
mM CaC12, and 0.25 mg/ml BSA) was prewarmed to 37~  ex- 
posed  to 10 ng/ml IL-3 for 10 rain, and then stimulated with a 
chemokine. After 20 min, the reaction was stopped on ice. Hista- 
mine and LTC4  were  measured  in  the  supematants  (11, 22). 
Priming with IL-3 enhances responsiveness to agonists and is re- 
quired for LTC  4 generation (11, 20, 22). 
Chemotaxis.  Chemotaxis of eosinophils was performed essen- 
tially as  described  (12). Briefly,  chemokines were added to  the 
lower wells  of a  48-well chemotactic  chamber  (Neuro  Probe, 
Cabin John, MD).  Cells were suspended  in Gey's solution sup- 
plemented with 20 mM Hepes and 0.25% BSA adjusted  to pH 
7.4  and placed  into the top wells (50,000  cells/well).  Migration 
across  a polycarbonate filter  (polyvinyl pyrrolidone free,  5-1am 
pore size; Nucleopore Corp., Pleasanton,  CA)  was assessed after 
50 rain at 37~  in 5% CO2. The migrated cells were counted mi- 
croscopically  after fixation and staining on the lower surface of 
the filter. 
Cytosolic-free Calcium [Ca2+]i Changes.  Purified  eosinophils 
were loaded with Fura-2/AM (0.3 nmol/106 cells) for 30 rain at 
37~  washed,  and resuspended  in HACM buffer. The cells (106 
cells/ml)  were  stimulated in a stirred  cuvette at  37~  and the 
fluorescence  changes monitored (12). In each experiment, maxi- 
mal and minimal fluorescence was calibrated by addition of 2 IxM 
ionomycin and 3 mM CaC12, followed by 10 mM MnCI  2. 
Actin Polymerization.  F-actin formation was assessed in eosi- 
nophils, according to Howard and Meyer (23). Eosinophils  (106 
cells/ml in HACM buffer) were prewarmed for 10 min, stimu- 
lated with a chemokine, and fixed after  15 s with 3% formalde- 
hyde in PBS  (pH 7.4)  containing 100 t.Lg/ml lysophosphatidyl- 
choline. After  10 min, the cells were stained  for 10 min in the 
dark with NBD-phallacidin (33 U/ml), and the intracellular fluo- 
rescence was monitored by FACScan  |  analysis. 
Respiratory Burst.  The respiratory burst was measured in eosi- 
nophils by lucigenin-dependent chemiluminescence. Samples of 
200  Ixl  eosinophil suspension  (106 cells/ml)  in HACM  buffer 
containing 100  IxM lucigenin were  placed  in microtiter plates 
thermostated  at  37~  stimulated with  a  chemokine,  and  the 
chemiluminescence  was monitored (24). 
Results  and  Discussion 
Synthetic analogues of full-length MCP-1  (76 residues), 
with truncations within the  10-residue NH2-terminal do- 
main preceding the  first  cysteine,  MCP-l(2-76)  through 
MCP-l(10-76)  (19),  were  tested  for  activity on basophil 
leukocytes.  As  shown  in  Fig.  1,  full-length MCP-1  in- 
duced the release of histamine, reflecting granule exocyto- 
sis, and the generation and release of LTC4, consistent with 
previous studies (9-11). For both responses, the concentra- 
tion of MCP-1 inducing half-maximal release was ~5  nM. 
Deletion of the  NH2-terminal residue,  yielding analogue 
MCP-1 (2-76), led to an ~50-fold decrease in potency, and 
deletion of the  following residue led  to  analogue MCP- 
1  (3-76), which was inactive up to a concentration of 1,000 
nM.  Some  activity was  again  detected  for  MCP-l(4-76) 
and MCP-1 (5-76), which were ~300- and 50-fold less po- 
tent than full-length MCP-1, respectively, whereas the fur- 
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Figure  1.  Action  of full-length MCP-1, 1-76, and NH2-terrmnally 
truncated analogues  on human basophil leukocytes. (A) Histamine  release 
(percentage of the total cellular  content) and LTC4 generation. The ana- 
logs MCP-1(3-76) and MCP-l(6-76) through MCP-1(10-76) were inac- 
tive up to 1,000 nM. Mean values of duplicate determinations  from one 
representative experiment  out of four. (/3) Relative potency of full-length 
MCP-I and analogues calculated on the basis of the ECs0. Mean values 
from four separate experiments  with cells from different  donors (range in 
parentheses) are shown. In each experiment, the potency of full-length 
MCP-1 was set to 100% and the relative  potency of the analogues  calcu- 
lated. The value for MCP-1  (4-76) was calculated  by extrapolation. 
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Figure 2.  In vitro chemotaxis ofhurruan eosinophils in response to full- 
length MCP-1,  MCP-l(2-76), and MCP-3.  Cell numbers per five high- 
power fields (HPF; ￿  are given. Mean values of triphcate determi- 
nations from one representative experiment out of seven are shown. 
ther  truncated  analogues  MCP-l(6-76)  through  MCP- 
1(10-76)  were  inactive. The  dramatic  loss  of potency  on 
basophils resulting from the deletion of the NH2-terminal 
residue demonstrates that the NH2  terminus is a major re- 
quirement for the induction  of histamine and leukotriene 
release. The present results are in general agreement with 
recent  observations  on  monocytic  THP-1  cells,  where 
MCP-1 (2-76) was shown to have a 100-fold lower binding 
affinity than flAl-length MCP-1. 
Because of the striking changes in function on NH2-ter- 
minal truncation, it was of interest to test the MCP-1  ana- 
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Figure 3.  Responses  of human eosinophils to MCP-l(2-76); compari- 
son with full-length MCP-1 and RANTES.  (A) Actin polymerization as 
assessed by the increase of filamentous actin-dependent fluorescence; (B) 
respiratory burst measured by chemiluminescence; (C)  [Ca2+]i changes 
induced by increasing concentrations of MCP-l(2-76). Representative 
experiments are shown. Number of experiments: 10 for A, 4 for B, and 3 
for C. If  not indicated otherwise, the agonist concentrations  were 100 nM. 
logues  on  eosinophil leukocytes  that  respond  to  MCP-3 
and  RANTES,  but  not  to  MCP-1  (12-15).  The  results 
were surprising: deletion of the NH2-terrmnal residue re- 
sulted in an MCP-1 analogue with marked activity on eosi- 
nophils. As shown  in  Fig. 2,  MCP-1(2-76)  is a  powerful 
chemoattractant for human eosinophils with similar efficacy 
and potency as MCP-3. Additional responses were studied 
to substantiate the eosinophil-activating  properties of MCP-1 
(2-76). In contrast to fuU-length MCP-1, the truncated an- 
alogue induced actin polymerization, a correlate of the mo- 
tor response of phagocytes, the respiratory burst reflecting 
the activation of the NADPH-oxidase, and a transient rise 
in  [Ca2+]i,  which  is  typical  for  agonists  acting  through 
seven-transmembrane,  G  protein-coupled  receptors  (25, 
26) (Fig. 3). These results show that MCP-1(2-76)  ehcits in 
eosinophil leukocytes the characteristic pattern of in vitro 
leukocyte responses to chemotactic stimulation. 
Full-length  MCP-1  and  all  truncated  analogues  were 
also tested on eosinophils for their ability to induce chemo- 
taxis  and  [Ca2+]i  changes.  The  results  with  analogues 
MCP-l(3-76)  through  MCP-l(10-76)  were  qualitatively 
similar  on  eosinophils  and  basophils.  Analogue  MCP-1- 
(3-76)  was  inactive,  weak  but  significant responses  were 
obtained  with  MCP-1(4-76)  and  MCP-l(5-76),  and  no 
activity  was  observed  upon  further  truncation  (Fig.  4). 
Full-length MCP-1  showed borderline chemotactic activ- 
ity in  some  but  not  all  experiments  and  did  not  induce 
[Ca2+]i changes (Fig. 4). 
After stimulation, chemokine receptors are characteristi- 
cally refractory to subsequent stimulation by the same or a 
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Figure 4.  Activities of full-length MCP-1  and NH2-terminally trun- 
cated analogues on human eosinophils. (A) Chemotaxis, comparison with 
MCP-3. The assays  were done at concentrations ranging between 10 and 
1,000 nM, and the mean values obtained at 100 nM in seven separate ex- 
periments are shown (range in parentheses). (B) [Ca2+]i changes. MCP-1 
and truncated analogues were applied at 50 riM, and after 90 s, 10 nM 
C5a was added to test for cell responsiveness. The analogues MCP-1- 
(6-76) through MCP-l(10-76)  were inactive. One out of three similar 
experiments is shown. 
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Figure  5.  Response of human eosi- 
nophils to MCP-1(2-76) after  pretreat- 
ment  with MCP-3, R_ANTES,  or 
MIP-la, all at  100 nM.  One repre- 
sentative experiment out  of three is 
shown. 
cross-reacting agonist.  Previous  studies  have  revealed  the 
presence of two CC chemokine receptors on eosinophils, 
one binding R.ANTES and MCP-3, and the other binding 
R_ANTES  and MIP-lo~ and,  with lower aflanity,  MCP-3 
(13,  15,  26).  Desensitization experiments were performed 
to gain information on the receptors involved in the activa- 
tion of eosinophils by MCP-l(2-76).  As shown in Fig.  5, 
the response to MCP-l(2-76) was prevented by prior stim- 
ulation with MCP-3  or R_ANTES but not MIP-lc~, sug- 
gesting that MCP-l(2-76) acts mainly through the receptor 
that recognizes R.ANTES  and MCP-3  but does not bind 
MIP-lc~. This conclusion is consistent with the observation 
that MCP-1(2-76)  had chemotactic activity comparable to 
that of MCP-3 and RANTES, and was clearly superior to 
MIP-lct, which is a weak stimulus of eosinophils (12,  26). 
This study demonstrates the critical role of the NH2 ter- 
minus for the  action of MCP-1  on basophils and eosino- 
phils. MCP-1  is a potent inducer of histamine and leuko- 
triene  release in basophils but lacks detectable activity on 
eosinophils.  Upon  deletion  of the  NH2-terminal  amino 
acid, the profile of activity of the chemokine changed dra- 
matically: its potency at inducing mediator release from ba- 
sophils fell 50-fold,  and  a  new  activity emerged,  chemo- 
taxis  for  eosinophils.  The  [Ca2+]i transients  induced  in 
eosinophils  by  MCP-1(2-76)  were  prevented  by  prior 
stimulation  with  MCP-3  or  RANTES,  indicating  that 
MCP-1(2-76)  acts through the RANTES/MCP-3  recep- 
tor (23).  Our results suggest that the receptor for MCP-1 
on basophils  and  the  receptor for KANTES/MCP-3  on 
eosinophils must be similar, although they clearly discrimi- 
nate between MCP-1  and MCP-1(2-76).  Similarity is also 
suggested by the observation that two truncation analogues, 
MCP-l(4-76)  and MCP-l(5-76),  were active, whereas the 
others,  MCP-l(3-76)  and  MCP-l(6-76)  through  MCP- 
1(10-76), were inactive on both eosinophils and basophils. 
The  major effect of the  deletion  of the  NH2-terminal 
residue of MCP-1  described here suggests processing at the 
NH  2 terminus as a potential mechanism for the regulation 
of the  potency  and  target  cell  selectivity of MCP-1  and 
other  CC  chemokines.  There  is  no  direct  information 
about  the  processing  of MCPs  by amino  peptidases,  but 
some  MCP  analogues  with  truncated  NH2-terminal  do- 
mains have been identified in cell  culture supernatants  (2). 
In this context, eotaxin, a novel chemokine discovered in 
guinea pigs, is of particular interest. Eotaxin was identified 
as the main attractant for eosinophils in a model of eosino- 
philic lung inflammation (27).  It has marked sequence sim- 
ilarity with  the  human  MCPs,  but  its  NHz-terminal do- 
main  (residues  preceding  the  first  cysteine)  consists  of 7 
instead of 10  residues  (28).  Comparison of the  activity of 
eotaxin on eosinophils, basophils, and monocytes may pro- 
vide useful information about the determinants for receptor 
recognition. 
Previous  studies  have  demonstrated  the  critical  role  of 
the NH2 terminus for the biological activity of CXC chemo- 
kines  on  neutrophils  (16,  17,  29).  Several  NH2-terminal 
variants of IL-8 and other CXC chemokines were found in 
the supernatants of cultured monocytes and tissue cells (25), 
and it was shown that NH2-terminal processing markedly 
enhances IL-8 activity (17).  However, a change in cellular 
and  receptor  selectivity,  as  described  here  as  the  conse- 
quence  of MCP-1  truncation,  has  never been  observed. 
Processing by specific amino peptidases must be considered 
as a regulatory mechanism for CC chemokine activities in 
the microenvironment of immune effector cells. 
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